Developing the VTX-1 liquid biopsy system: Fast and label-free enrichment of circulating tumor cells
A new article in the February 2018 issue of SLAS Technology describes a new platform that could change the way cancer is diagnosed and treated by automating the isolation of circulating tumor cells (CTCs) directly from cancer patient blood. Entitled Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System, this article provides unique insight into the development of a commercial system that has the potential to change the standard of care in cancer diagnosis and treatment.
CTCs can be isolated from a simple blood draw and may be representative of the diverse cancer patient biology because tumor cells are circulating in the blood stream from multiple tumor sites. The VTX-1 Liquid Biopsy System was designed to automate the isolation of clinically relevant CTC populations, making the CTCs available for easy analysis by a variety of techniques. In this publication, the transition from a cutting-edge microfluidic innovation in the research setting to a commercial, automated system for isolating CTCs directly from whole blood is outlined.
A number of improvements are reviewed as the technology transitioned into a commercial product. These improvements include better material for the microfluidic fabrication, automating the fluid processing in the chip, and the optimization of isolation protocols. The commercial VTX-1 Liquid Biopsy System is shown to recover spiked breast and lung cancer cell lines at a rate of 69% and 79.5% respectively while achieving a purity as low as <100 white blood cells per mL of blood processed.
To show the utility of the platform for cancer research, several downstream applications are demonstrated on the CTCs isolated by the VTX-1. Clonogenic and cell invasion assays demonstrate that the cells isolated by the VTX-1 are intact and undisturbed by the processing, resulting in direct access to the cell's cancer biology. To demonstrate that the VTX-1 can also process mouse samples, CTCs are isolated from two patient-derived orthotopic xenograft mouse models.
More information: Cristina Zavaleta et al, Theranostic Nanoparticles for Tracking and Monitoring Disease State, SLAS TECHNOLOGY: Translating Life Sciences Innovation (2017). DOI: 10.1177/2472630317738699